CU Logo University of Colorado Anschutz Medical Campus
Back to Results

Efficacy and mechanisms of dapagliflozin in promoting kidney function and cardiovascular health in kidney transplant recipients

Primary Objective

This research study is being conducted to examine the effects of dapagliflozin on kidney function, blood vessel function and heart function. We are studying the effects/impact of dapagliflozin (a SGLT2 inhibitor) on: - Kidney function - Protein in the urine - Blood vessel function - Heart function

Is This Study For You?

Let's Get Started!

Description

Main procedures done in the study: - Physical exam and medical history - Blood draw - Blood pressure - Blood vessel function testing - Urine collection - Kidney function measures - Kidney and cardiac MRI You will take study drug daily for 12 months You will have approximately 7 study visits where the above procedures will be conducted over 12 months. Testing will take place at the Kidney Disease Research Center on the University of Colorado Anschutz Medical Campus. Participants will receive information regarding their overall health status; including testing for blood pressure, kidney function levels, diabetes control. Compensation provided.

Details
Age
Adult
Eligibility
- History of kidney transplant - History of diabetes type 2 or posttransplant diabetes mellitusWe need men and women who are: - Age 18 years and older - History of kidney transplant - History of diabetes type 2 or posttransplant diabetes mellitus - Women must not be pregnant or breastfeeding - Urine albumin to creatinine ratio of 30-5000 mg/g Exclusionary criteria: - Current use of dapagliflozin or another SGLT2 inhibitor - Type 1 diabetes
Locations

Renal Research Center
University of Colorado Hospital

Principal Investigator
Photograph of Jessica Kendrick

Jessica Kendrick

Study ID

Protocol Number: 23-1360

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers